Pomalidomide Capsule
Product Images NDC 60505-4497

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pomalidomide (NDC 60505-4497). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Btl-lbl-1mg-21s (Btl Lbl 1mg 21s)

Pomalidomide Capsules 1 mg oral dosage form packaging label by Apotex Corp. The label indicates a 21 capsule count and includes storage instructions, a warning about potential human birth defects, and a barcode. Manufactured by Apotex Inc. in Toronto, Canada, and for Apotex Corp. in Weston, Florida.*

FDA Label Image

Btl-lbl-2mg-21s (Btl Lbl 2mg 21s)

The label for Pomalidomide Capsules 2 mg oral capsules from Apotex Corp. The package contains 21 capsules. The label includes storage instructions, a warning about potential human birth defects, the NDC number 60505-4498-2, and manufacturer information for Apotex Inc. in Toronto and Apotex Corp. in Florida. The label also instructs pharmacists to dispense the enclosed medication guide and shows a barcode with an 'Open Here' indicator.*

FDA Label Image

Btl-lbl-3mg-21s (Btl Lbl 3mg 21s)

Pomalidomide 3 mg capsules label displaying the product name, strength, and form. The label indicates a quantity of 21 capsules, the NDC 60505-4499-2, and directions to store between 20°-25°C with excursions permitted from 15°-30°C. The label includes a birth defects warning, dispensing instructions, manufacturer Apotex Inc. in Toronto, Ontario, and Apotex Corp. in Weston, Florida, with a barcode on the right side.*

FDA Label Image

Btl-lbl-4mg-21s (Btl Lbl 4mg 21s)

Label for Pomalidomide 4 mg oral capsules by Apotex Corp. The label states the strength as 4 mg per capsule and includes packaging information for 21 capsules. Storage instructions note maintaining 20°-25°C with permitted excursions, dispensing in a tight container. Warning highlights potential for human birth defects. Manufacturer contact details for Apotex Inc. in Toronto and Apotex Corp. in Florida are also present along with a barcode.*

FDA Label Image

Figure-1 (Figure 1)

A Kaplan-Meier survival curve chart comparing progression-free survival over months between two treatment groups: HD-DEX (blue solid line) and POM+LD-DEX (red dashed line). The vertical axis shows the proportion of subjects surviving without progression, and the horizontal axis shows time in months. The chart includes risk tables and statistical values such as hazard ratio and p-value.*

FDA Label Image

Figure-2 (Figure 2)

A Kaplan-Meier survival curve chart depicting overall survival proportions over a 24-month period, comparing two treatment groups: HD-DEX (blue line) and POM+LD-DEX (red dashed line). The x-axis represents overall survival time in months, and the y-axis shows the proportion of subjects surviving. The chart includes a risk table indicating the number of subjects at risk in each group at various time points below the graph.*

FDA Label Image

Structure (Structure)

Chemical structure of pomalidomide, the active ingredient in Pomalidomide capsules by Apotex Corp. The structure shows two fused rings, including an amino group and multiple carbonyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.